Source comparison
Ipam: [Type] Comparison
Research labs often choose between multiple growth hormone secretagogues depending on study design. Here's how Ipam compares to the most common alternatives based on receptor selectivity, off-target effects, and practical research applications. Ipam (Ipamoreli
This comparison does not assign a generated winner or score.
- Research labs often choose between multiple growth hormone secretagogues depending on study design. Here's how Ipam compares to the most common alternatives based on receptor selectivity, off-target effects, and practical research applications.
- Ipam (Ipamorelin)
- Moderate (2–3× baseline GH)
- None
- Selective GH studies without hormonal confounds
- Cleanest tool for isolated GH pathway research
- GHRP-6
- High (3–5× baseline GH)
- Moderate increase
- Strong (20–40 min onset)
- Appetite and GH co-elevation studies
- High potency but too many off-target effects for clean GH data
- GHRP-2
- High (4–6× baseline GH)
- Significant increase (40–80%)
- Mild
- Studies where cortisol co-elevation is acceptable
- Potent but cortisol confound limits metabolic research
- Hexarelin
- Very High (5–8× baseline GH)
- Significant increase
- Moderate
- Maximal GH stimulation studies
- Desensitizes rapidly; not suitable for chronic protocols
- MK-677 (Ibutamoren)
- Sustained elevation (24-hour duration)
- Moderate to strong
- Long-duration GH elevation without injections
- Oral bioavailability but appetite stimulation limits body comp studies
- Ipam sits in the middle of the potency spectrum but at the top of the selectivity spectrum. If your endpoint is growth hormone activity without cortisol, prolactin, or appetite interference, Ipam is the clear choice. If maximal GH output is the goal and off-target effects are acceptable, Hexarelin or GHRP-2 may be more appropriate. But expect rapid desensitization with Hexarelin and cortisol-mediated insulin resistance with GHRP-2.
- Our experience with researchers across metabolic, aging, and body composition studies consistently shows that Ipam produces the most reproducible results over multi-week protocols. The lack of receptor desensitization at therapeutic doses means GH response curves remain stable across repeated administrations. A critical feature for longitudinal studies.